Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly's newly launched oral weight loss drug Foundayo recorded flat prescription growth across its first five weeks on the market, trailing the rollout pace of Novo Nordisk's oral Wegovy formulation. The stagnant uptake comes despite Lilly commanding a 60% share of the U.S. weight loss drug market.

Analysts attribute the sluggish start to delayed pharmacy coverage and typical friction surrounding new drug formulations rather than fundamental demand issues. Foundayo's oral delivery represents a fresh approach in Lilly's obesity franchise, and broader insurance reimbursement typically lags commercial launch by several weeks to months.

The five-week prescription plateau contrasts with the momentum Novo Nordisk achieved with its oral Wegovy variant, intensifying scrutiny on whether Lilly can maintain its dominant market position. The company's deep pipeline in weight loss therapeutics offers a buffer, but early script trends often signal prescriber confidence and payer receptivity—two factors critical to sustained revenue ramps in the multi-billion-dollar obesity market.